{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:07:15Z","timestamp":1792552035259,"version":"4.5.0"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Androgen receptor (AR) is expressed in 60-70% of breast cancers (BCs) and the availability of anti-AR compounds, currently used for treating prostate cancer, paves the way to tackle specifically AR-positive BC patients. The prognostic and predictive role of AR in BC is a matter of debate, since the results from clinical trials are not striking, probably due to both technical and biological reasons. In this review, we aimed to highlight WHAT is AR, describing its structure and functions, WHAT to test and HOW to detect AR, WHERE AR should be tested (on primary tumor or metastasis) and WHY studying this fascinating hormone receptor, exploring and debating on its prognostic and predictive role. We considered AR and its ratio with other hormone receptors, analyzing also studies including patients with ductal carcinoma\n                    <jats:italic>in situ<\/jats:italic>\n                    and with early and advanced BC, as well. We also emphasized the effects that both other hormone receptors and the newly emerging androgen-inducible non coding RNAs may have on AR function in BC pathology and the putative implementation in the clinical setting. Moreover, we pointed out the latest results by clinical trials and we speculated about the use of anti-AR therapies in BC clinical practice.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2022.977331","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T01:09:54Z","timestamp":1661821794000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Androgen receptor in breast cancer: The \u201c5W\u201d questions"],"prefix":"10.3389","volume":"13","author":[{"given":"Sara","family":"Ravaioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Maltoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pasculli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Parrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Giudetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Tumedei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pirini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bravaccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840201)53:3+<630::aid-cncr2820531308>3.0.co;2-3","article-title":"Steroid-hormone receptors in breast cancer","volume":"53","author":"Wittliff","year":"1984","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U","article-title":"The value of estrogen and progesterone receptors in the treatment of breast cancer","volume":"46","author":"Osborne","year":"1980","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials","volume":"378","author":"Abe","year":"2011","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx397","article-title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","volume":"28","author":"Fujii","year":"2017","journal-title":"Ann Oncol"},{"key":"B7","article-title":"Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer","volume":"37","author":"Knight","year":"1977","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12920-015-0129-6","article-title":"Development and verification of the PAM50-based prosigna breast cancer gene signature assay","volume":"8","author":"Wallden","year":"2015","journal-title":"BMC Med Genomics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3260-7","article-title":"Androgen receptor-positive triple negative breast cancer: A unique breast cancer subtype","volume":"21","author":"McGhan","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt319","article-title":"Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis","volume":"106","author":"Vera-Badillo","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11532","article-title":"Androgen receptors frequently are expressed in breast carcinomas: Potential relevance to new therapeutic strategies","volume":"98","author":"Moinfar","year":"2003","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.54","article-title":"Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the nurses\u2019 health study","volume":"24","author":"Collins","year":"2011","journal-title":"Mod Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0417","article-title":"The role of the AR\/ER ratio in ER-positive breast cancer patients","volume":"25","author":"Rangel","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197827","article-title":"Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features","volume":"13","author":"Astvatsaturyan","year":"2018","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1200\/jco.2015.33.15_suppl.1003","article-title":"Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)","author":"Traina","year":"2015","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4103\/1008-682X.122590","article-title":"Human androgen deficiency: insights gained from androgen receptor knockout mouse models","volume":"16","author":"Rana","year":"2014","journal-title":"Asian J Androl"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00492","article-title":"The androgen receptor in breast cancer","volume":"9","author":"Giovannelli","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2223-4683.2013.09.02","article-title":"Androgen receptor epigenetics","volume":"2","author":"Cai","year":"2013","journal-title":"Transl Androl Urol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41419-021-03402-7","article-title":"The androgen receptor\/filamin a complex as a target in prostate cancer microenvironment","volume":"12","author":"Di Donato","year":"2021","journal-title":"Cell Death Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2019.00651","article-title":"Non-nuclear AR signaling in prostate cancer","volume":"7","author":"Zamagni","year":"2019","journal-title":"Front Chem"},{"key":"B21","first-page":"3","article-title":"Androgen receptor structure, function and biology: From bench to bedside","volume":"37","author":"Davey","year":"2016","journal-title":"Clin Biochem Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1210\/me.2007-0158","article-title":"Ligand-independent activation of androgen receptors by rho GTPase signaling in prostate cancer","volume":"22","author":"Lyons","year":"2008","journal-title":"Mol Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2006.12.009","article-title":"Src-dependent signalling pathway regulation by sex-steroid hormones: Therapeutic implications","volume":"39","author":"Migliaccio","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr3599","article-title":"Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide","volume":"16","author":"Cochrane","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3934-5","article-title":"Prognostic significance of androgen receptor expression in invasive breast cancer: Transcriptomic and protein expression analysis","volume":"159","author":"Aleskandarany","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0452","article-title":"Androgen receptor inhibits estrogen receptor-\u03b1 activity and is prognostic in breast cancer","volume":"69","author":"Peters","year":"2009","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3082-8","article-title":"AR collaborates with ER\u03b1 in aromatase inhibitor-resistant breast cancer","volume":"147","author":"Rechoum","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00118-10","article-title":"Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation","volume":"30","author":"Stender","year":"2010","journal-title":"Mol Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-009-0436-8","article-title":"Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells","volume":"121","author":"De Amicis","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01168-7","article-title":"The androgen receptor is a tumor suppressor in estrogen receptor\u2013positive breast cancer","volume":"27","author":"Hickey","year":"2021","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3609-7","article-title":"Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ER\u03b1-positive breast cancer","volume":"154","author":"Ciupek","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/me.2011-1314","article-title":"Research resource: Interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor \u03b1 in luminal breast cancer cells","volume":"26","author":"Need","year":"2012","journal-title":"Mol Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1593\/neo.08274","article-title":"A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer","volume":"10","author":"Naderi","year":"2008","journal-title":"Neoplasia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00573","article-title":"Androgen receptor in breast cancer: From bench to bedside","volume":"11","author":"Chen","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0912","article-title":"Steroid receptor regulation of epidermal growth factor signaling through src in breast and prostate cancer cells: Steroid antagonist action","volume":"65","author":"Migliaccio","year":"2005","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.09.004","article-title":"Pairing beyond the seed supports MicroRNA targeting specificity","volume":"64","author":"Broughton","year":"2016","journal-title":"Mol Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.121","article-title":"Posttranscriptional upregulation by microRNAs","volume":"3","author":"Vasudevan","year":"2012","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.proghi.2016.06.001","article-title":"Intracellular and extracellular microRNA: An update on localization and biological role","volume":"51","author":"Makarova","year":"2016","journal-title":"Prog Histochem Cytochem"},{"key":"B40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.semcancer.2020.05.017","article-title":"Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention","volume":"72","author":"Sengupta","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/s41467-019-09649-1","article-title":"Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.08.069","article-title":"LncRNA HOTAIR enhances the androgen-Receptor-Mediated transcriptional program and drives castration-resistant prostate cancer","volume":"13","author":"Zhang","year":"2015","journal-title":"Cell Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7207","article-title":"Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor","volume":"30","author":"Kampa","year":"2017","journal-title":"Oncogene"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.030098","article-title":"miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer","volume":"284","author":"Epis","year":"2009","journal-title":"J Biol Chem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.131","article-title":"miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients","volume":"108","author":"Hagman","year":"2013","journal-title":"Br J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.425","article-title":"Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells","volume":"32","author":"Shi","year":"2013","journal-title":"Oncogene"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp510","article-title":"Expression of androgen receptors in primary breast cancer","volume":"21","author":"Park","year":"2010","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00795-010-0494-3","article-title":"Androgens in human breast carcinoma","volume":"43","author":"Suzuki","year":"2010","journal-title":"Med Mol Morphol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00449-08","article-title":"Activated androgen receptor downregulates e-cadherin gene expression and promotes tumor metastasis","volume":"28","author":"Liu","year":"2008","journal-title":"Mol Cell Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0926","article-title":"Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo","volume":"14","author":"Barton","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B52","article-title":"Identification of androgen-responsive microRNAs and androgen-related genes in breast cancer","volume":"33","author":"Nakano","year":"2013","journal-title":"Anticancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2151","article-title":"Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer","volume":"44","author":"Lyu","year":"2014","journal-title":"Int J Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23196","article-title":"Androgen receptor\/let-7a signaling regulates breast tumor-initiating cells","volume":"9","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6781","article-title":"Interrelation of androgen receptor and miR-30a and miR-30a function in ER(-), PR(-), AR(+) MDA-MB-453 breast cancer cells","volume":"14","author":"Lyu","year":"2017","journal-title":"Oncol Lett"},{"key":"B56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3892\/mmr.2016.6019","article-title":"Differential microRNA expression is associated with androgen receptor expression in breast cancer","volume":"15","author":"Shi","year":"2017","journal-title":"Mol Med Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.10841","article-title":"Differential expression and androgen regulation of microRNAs and metalloprotease 13 in breast cancer cells","volume":"41","author":"Ahram","year":"2017","journal-title":"Cell Biol Int"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7207","article-title":"Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor","volume":"7","author":"Casaburi","year":"2016","journal-title":"Oncotarget"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2018.06.094","article-title":"Dihydrotestosterone regulates expression of CD44 via miR-328-3p in triple-negative breast cancer cells","volume":"675","author":"Al-Othman","year":"2018","journal-title":"Gene"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-018-0123-6","article-title":"An androgen receptor negatively induced long non-coding RNA ARNILA binding to miR-204 promotes the invasion and metastasis of triple-negative breast cancer","volume":"25","author":"Yang","year":"2018","journal-title":"Cell Death Differ"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.04.002","article-title":"Androgen receptor in breast cancer: A wolf in sheep\u2019s clothing? a lesson from prostate cancer","volume":"2020","author":"Salvi","year":"","journal-title":"Semin Cancer Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/J.CCELL.2018.03.014","article-title":"A comprehensive pan-cancer molecular study of gynecologic and breast cancers","volume":"33","author":"Berger","year":"2018","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41523-019-0142-6","article-title":"Androgen receptor gene expression in primary breast cancer","volume":"5","author":"Vidula","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.yexcr.2005.02.027","article-title":"Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis","volume":"307","author":"Kampa","year":"2005","journal-title":"Exp Cell Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-12-0065","article-title":"An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity","volume":"19","author":"Moore","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0480","article-title":"AR expression in breast cancer CTCs associates with bone metastases","volume":"16","author":"Aceto","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32209","article-title":"Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer","volume":"145","author":"de Kruijff","year":"2019","journal-title":"Int J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088525","article-title":"Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options","volume":"9","author":"Gasparini","year":"2014","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1186\/s12885-015-1897-2","article-title":"Androgen receptor status is highly conserved during tumor progression of breast cancer","volume":"15","author":"Grogg","year":"2015","journal-title":"BMC Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4904-x","article-title":"The prognostic value of androgen receptors in breast cancer subtypes","volume":"72","author":"Kraby","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12114","article-title":"Receptor conversion in metastatic breast cancer: A prognosticator of survival","volume":"7","author":"Xiangying","year":"2016","journal-title":"Oncotarget"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.05.006","article-title":"Androgen receptor expression in breast cancer: What differences between primary tumor and metastases","volume":"11","author":"Bronte","year":"2018","journal-title":"Transl Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2717","article-title":"Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer","volume":"77","author":"Cejalvo","year":"2017","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000625","article-title":"Androgen receptors in resected ductal carcinoma in situ of breast: Novel insights with possible implications for testing and targeted endocrine chemoprevention trials","volume":"27","author":"Oshilaja","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000582","article-title":"Are androgen and estrogen receptors in DCIS patients prognostic indicators of relapse independently of treatment","volume":"27","author":"Ravaioli","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/iep.12253","article-title":"Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy","volume":"98","author":"Ravaioli","year":"2017","journal-title":"Int J Exp Pathol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.5301\/jbm.5000163","article-title":"Role of androgen and estrogen receptors as prognostic and potential predictive markers of ductal carcinoma in situ of the breast","volume":"30","author":"Tumedei","year":"2015","journal-title":"Int J Biol Markers"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00112-8","article-title":"The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters","author":"Kuenen-Boumeester","year":"1996","journal-title":"Eur J Cancer Part A"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4239-3","article-title":"Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy","volume":"18","author":"Bronte","year":"2018","journal-title":"BMC Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00137","article-title":"Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population","volume":"9","author":"Bravaccini","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1393505","article-title":"Evaluation of androgen receptor in relation to estrogen receptor (AR\/ER) and progesterone receptor (AR\/PgR): A new must in breast cancer","volume":"2019","author":"Bronte","year":"2019","journal-title":"J Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0761-y","article-title":"Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers","volume":"124","author":"Castellano","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt183","article-title":"A simple and reproducible prognostic index in luminal ER-positive breast cancers","volume":"24","author":"Castellano","year":"2013","journal-title":"Ann Oncol"},{"key":"B86","article-title":"Androgen receptor as a targeted therapy for breast cancer","volume":"2","author":"Garay","year":"2012","journal-title":"Am J Cancer Res"},{"key":"B87","article-title":"Androgen receptors in operable breast cancer: Relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment","volume":"18","author":"Soreide","year":"1992","journal-title":"Eur J Surg Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2021","article-title":"Androgen receptor expression and breast cancer survival in postmenopausal women","volume":"17","author":"Hu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.20.5406","article-title":"Steroid-induced androgen receptor-oestradiol receptor beta-src complex triggers prostate cancer cell proliferation","volume":"19","author":"Migliaccio","year":"2000","journal-title":"EMBO J"},{"key":"B90","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.trecan.2015.12.001","article-title":"Targeting Androgen\/Estrogen receptors crosstalk in cancer","volume":"2","author":"Karamouzis","year":"2016","journal-title":"Trends Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-9923-6","article-title":"Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: Tamoxifen agonist effects dominate in the presence of an aromatase inhibitor","volume":"112","author":"Harvell","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-9897-4","article-title":"Molecular signatures of neoadjuvant endocrine therapy for breast cancer: Characteristics of response or intrinsic resistance","volume":"112","author":"Harvell","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116271","article-title":"Related individuals with different androgen receptor gene deletions","volume":"91","author":"MacLean","year":"1993","journal-title":"J Clin Invest"},{"key":"B94","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1615\/critreveukargeneexpr.v5.i2.10","article-title":"Androgen receptor: an overview","volume":"5","author":"Chang","year":"1995","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0243","article-title":"Complexities of androgen receptor signalling in breast cancer","volume":"21","author":"McNamara","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1210\/er.2001-0031","article-title":"Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone","volume":"24","author":"Labrie","year":"2003","journal-title":"Endocr Rev"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.steroids.2011.10.002","article-title":"Androgens and breast cancer","volume":"77","author":"Kotsopoulos","year":"2012","journal-title":"Steroids"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.tps640","article-title":"A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer","volume":"33","author":"Trudeau","year":"2015","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2339","article-title":"A phase I\/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancer","volume":"23","author":"Schwartzberg","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-16-0167","article-title":"Cooperative dynamics of AR and ER activity in breast cancer","volume":"14","author":"D\u2019Amato","year":"2016","journal-title":"Mol Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1080\/gye.16.2.113.120","article-title":"Testosterone and 5\u03b1-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines","volume":"16","author":"Ortmann","year":"2002","journal-title":"Gynecol Endocrinol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0320793","article-title":"Inhibition of MCF-7 breast cancer cell proliferation by 5\u03b1-dihydrotestosterone; a role for p21Cip1\/Waf1","volume":"32","author":"Greeve","year":"2004","journal-title":"J Mol Endocrinol"},{"key":"B103","article-title":"Influence of dehydroepiandrosterone and 5-en-androstene-3\u03b2 17\u03b2-diol on the growth of MCF-7 human breast cancer cells induced by 17\u03b2-estradiol","volume":"12","author":"Boccuzzi","year":"1992","journal-title":"Anticancer Res"},{"key":"B104","article-title":"Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor \u03b1","volume":"59","author":"Maggiolini","year":"1999","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2011.02523.x","article-title":"Dehydroepiandrosterone (DHEA)-a precursor steroid or an active hormone in human physiology (CME)","volume":"8","author":"Traish","year":"2011","journal-title":"J Sex Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1677\/joe.1.06264","article-title":"Is dehydroepiandrosterone a hormone","volume":"187","author":"Labrie","year":"2005","journal-title":"J Endocrinol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1006\/frne.2001.0216","article-title":"DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology","author":"Labrie","year":"2001","journal-title":"Front Neuroendocrinol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1177\/019262338601400312","article-title":"Inhibition of tumor development by dehydroepiandrosterone and related steroids","volume":"14","author":"Schwartz","year":"1986","journal-title":"Toxicol Pathol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3892\/or-00000867","article-title":"Dehydroepiandrosterone intake protects against 7,12-dimethylbenz(a) anthracene-induced mammary tumor development in the obese zucker rat model","volume":"24","author":"Hakkak","year":"2010","journal-title":"Oncol Rep"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1350","article-title":"Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism","volume":"7","author":"Shilkaitis","year":"2005","journal-title":"Breast Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1393505","DOI":"10.1634\/theoncologist.2018-0243","article-title":"Phase II study of dehydroepiandrosterone in androgen receptor-positive metastatic breast cancer","volume":"24","author":"Pietri","year":"2019","journal-title":"Oncologist"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8529(18)30275-5","article-title":"Control of adrenal androgen secretion","volume":"20","author":"Parker","year":"1991","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.1020","article-title":"Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+\/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study","volume":"39","author":"Palmieri","year":"2021","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1038\/s41598-019-41016-4","article-title":"Androgens induce invasiveness of triple negative breast cancer cells through AR\/Src\/PI3-K complex assembly","volume":"9","author":"Giovannelli","year":"2019","journal-title":"Sci Rep"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.11.136","article-title":"Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction","volume":"111","author":"Sang","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1693","article-title":"A randomized placebo controlled phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer","volume":"26","author":"Krop","year":"2020","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s13058-014-0406-x","article-title":"PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors","volume":"16","author":"Lehmann","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13583","article-title":"A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer","volume":"26","author":"Yuan","year":"2020","journal-title":"Oncologist"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3114","article-title":"Amplification and protein expression of androgen receptor gene in prostate cancer cells: Fluorescence in situ hybridization analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"key":"B120","doi-asserted-by":"publisher","first-page":"viii120","DOI":"10.1093\/annonc\/mdy272.356","article-title":"368TiP - START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)","volume":"29","author":"Bonnefoi","year":"2018","journal-title":"Ann Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9030021","article-title":"AR signaling in breast cancer","volume":"9","author":"Rahim","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1159\/000484300","article-title":"Androgen receptor expression and bicalutamide antagonize androgen receptor inhibit \u03b2-catenin transcription complex in estrogen receptor-negative breast cancer","volume":"43","author":"Huang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.8899","article-title":"Complete response of metastatic androgen receptor-positive breast cancer to bicalutamide: Case report and review of the literature","volume":"34","author":"Arce-Salinas","year":"2016","journal-title":"J Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4813-z","article-title":"Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer","volume":"171","author":"Bardia","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw067","article-title":"A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)","volume":"27","author":"Bonnefoi","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.977331\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T01:10:06Z","timestamp":1661821806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.977331\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":126,"alternative-id":["10.3389\/fendo.2022.977331"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.977331","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"article-number":"977331"}}